No current positioning snapshot.
Current snapshotPublic companyResearch currentFresh
Varex Imaging Corp
Intervene · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Intervene exposure in Healthspan Infrastructure.
Varex Imaging supplies X-ray tubes, flat-panel detectors, and replacement components across CT/radiography OEM and aftermarket channels
Catalysts
PENDING ACQUISITION (not delisted): Teledyne to acquire Varex at $18.90 cash/share via Detect Merger Sub - merger agreement 8-10-26; special stockholder meeting 10-28-26 (record date 9-16, 42.46M shares); close expected early 2027. Terminal merger-arb: upside capped at $18.90, downside on vote/regulatory failure. Bid history in DEFM14A: Teledyne opened at $16.50 (6-30 letter); Sponsor B unsolicited interest 4-20-26.
Invalidation
needs primary source validation — pending deep-dive research. Placeholder: (1) thesis chain breaks on primary-source evidence, (2) named revenue/customer concentration risk, (3) margin compression or competitive displacement
Latest change
· Coverage moved from — to Added to coverage.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
needs primary source validation — no X/Reddit signal yet
Lower-confidence snapshotTarget price: $19.00
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Toll Road Tier
- BODY_SHOP
2026-10-28 · merger_vote
Timestamped research update
Deep research update
252 words · Updated 22 Oct 2026 · 3 sources
Research in development: this latest 252-word update is published for context while it is expanded toward Guide-level depth (1,000+ words).
Varex Imaging Corp (None, CIK 0001681622) — US-listed company materially exposed to Medical Imaging Systems.
Qualitative only — not yet verified against a filing.
Varex is generally described in its SEC filings as a supplier of X-ray imaging components to medical and industrial imaging original equipment manufacturers. The exact business description must be taken from Item 1 of the latest 10-K.
- Revenue mix by segment, medical vs. industrial: needs primary source validation
- Unit economics: needs primary source validation
- Gross margin: needs primary source validation
- Operating margin: needs primary source validation
- Monetization model: component sales plus aftermarket tube/service revenue; exact split needs primary source validation
- Top customers named from filings: needs primary source validation — many component suppliers do not disclose customer names, and may instead report “no customer individually exceeded 10%” or similar.
I will not state segment percentages, dollar revenue, margins, or growth rates because they cannot be traced to a retrieved filing in this session.
No customer names can be sourced from filings in this session.
Likely archetypes from the business model:
- Medical imaging OEMs
- Industrial inspection and security equipment OEMs
- Aftermarket service providers
- Government or port/airport security integrators
Specific named customers, if any, must come from the 10-K or investor-disclosed materials. I will not invent a customer.
Varex Imaging supplies X-ray tubes, flat-panel detectors, and replacement components across CT/radiography OEM and aftermarket channels
- Varex Imaging supplies X-ray tubes, flat-panel detectors, and replacement components across CT/radiography OEM and aftermarket channels source
- Varex Imaging Corp — SEC EDGAR company filings source
| parameter | value | source URL + document identifier | tier | measured/derived/assumed | cross-verified |
|---|---|---|---|---|---|
| Revenue | needs primary source validation | needs primary source validation | needs primary source validation | needs primary source validation | single-source required |
| Segment mix | needs primary source validation | needs primary source validation | needs primary source validation | needs primary source validation | single-source required |
| Gross margin | needs primary source validation | needs primary source validation | needs primary source validation | needs primary source validation | single-source required |
| Operating margin | needs primary source validation | needs primary source validation | needs primary source validation | needs primary source validation | single-source required |
| Unit shipments | needs primary source validation | needs primary source validation | needs primary source validation | needs primary source validation | single-source required |
| Customer concentration | needs primary source validation | needs primary source validation | needs primary source validation | needs primary source validation | single-source required |
_Pending primary-source company deep-dive._
Qualitative only — to be confirmed in the 10-K Item 1.
Varex’s core products are generally:
- X-ray tubes
- Flat-panel digital detectors
- High-voltage connectors and imaging software
- Service and replacement components
These products enable medical imaging systems such as CT, fluoroscopy, radiography, mammography, oncology, and industrial applications such as non-destructive testing, security screening, and cargo inspection.
An X-ray tube generates X-rays by accelerating electrons from a cathode to an anode; the resulting X-rays pass through a patient or object onto a detector. Flat-panel detectors convert X-rays into digital images.
Likely substitutes include:
- OEM-owned or captive X-ray tube programs
- Alternative detector suppliers
- Other imaging modalities such as ultrasound, MRI, or alternative detector technologies
- Lower-cost suppliers, especially for commodity detector panels
This list is general and must be verified against the filing’s competition section.
Likely moats include:
- Precision vacuum/high-voltage component manufacturing
- Long OEM qualification cycles
- Regulatory, ISO, and quality-system requirements
- Installed-base replacement demand for tubes
- Intellectual property and trade-secret process know-how
Pricing power must be assessed from filing data: gross margin trends, whether pricing is contractual with OEMs, and whether aftermarket replacement tube revenue carries higher margins. No conclusion can be sourced in this environment. needs primary source validation
_Pending primary-source company deep-dive._
The bullish or stable thesis for VREX would be challenged by:
- Gross margin compression without offsetting price increases or cost reductions
- A major medical imaging OEM insourcing X-ray tube or detector production
- Loss of a large OEM qualification or platform win
- Industrial/security demand decline from lower infrastructure or border-security spending
- Accelerating detector commoditization and ASP erosion
- Regulatory action or quality-system failure causing shipment delays or recalls
- Working capital deterioration from inventory buildup or receivables stress
Each of these must be tested against filings and primary industry data before conviction scoring.
INTACT (exposure surfaced from technology map; no capital allocation)
Primary and supporting material
Sources
3 sources preserved from the latest qualified research update.